EP
GSK icon

Eudaimonia Partners’s GSK GSK Stock Holding History

Eudaimonia Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,780
Closed -$369K – 406
2022
Q1 		$369K Buy
+6,780
New +$368K 0.06% 286
2021
Q3 		$291K Buy
6,092
+92
+2% +$4.62K 0.05% 313
2021
Q2 		$299K Buy
6,000
+1,782
+42% +$85.6K 0.06% 301
2021
Q1 		$188K Sell
4,218
-580
-12% -$26.3K 0.04% 342
2020
Q4 		$221K Sell
4,798
-37
-0.8% -$1.7K 0.05% 294
2020
Q3 		$227K Sell
4,835
-239
-5% -$12K 0.06% 262
2020
Q2 		$259K Sell
5,074
-213
-4% -$10.9K 0.1% 208
2020
Q1 		$250K Buy
5,287
+516
+11% +$27.5K 0.11% 190
2019
Q4 		$280K Buy
+4,771
New +$265K 0.11% 199

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Eudaimonia Partners's GSK Position: Q2 2022 in Review

Eudaimonia Partners sold out of GSK (GSK) in Q2 2022, closing a stake of 6,780 shares — an estimated $369K sold.

Eudaimonia Partners first reported a position in GSK in Q4 2019 and held it in 9 quarters. The position peaked at $369K in Q1 2022. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

  • Eudaimonia Partners reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
  • Eudaimonia Partners sold 6,780 GSK shares in Q2 2022, an estimated $369K.
  • Eudaimonia Partners first reported a position in GSK in Q4 2019 and held it in 9 quarters.
  • Eudaimonia Partners's GSK position peaked at $369K in Q1 2022.
  • 900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Eudaimonia Partners's 13F filing for Q2 2022, filed 9 Aug 2022.